Novo Nordisk A/S (NVO) Earnings

Novo Nordisk A/S

NVO · NYSE

Sep 2026upcoming

Next quarter

Expected to report Nov 4, 2026 — estimated from last year’s reporting date.

Consensus is $0.78 EPS for Sep 2026 across 4 estimates, ranging $0.74 to $0.85.

NVO Jun 2026

Reported Aug 4, 2026

: 17.07%
: +0.56%

: $0.82
: $0.96
: —
: —

Our read on this quarter has not been written yet. The filed figures and the source documents are above and below.

Symbol: NVO
Type: Stock
Sector: Health Care
Industry: Pharmaceutical Preparations
Exchange: NYSE

Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 66,700 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.

Key Issues

Bullish view

Novo Nordisk has several promising GLP-1 medicines in its pipeline and is described as a leader in diabetes and obesity treatments, giving it assets to sustain the franchise.

Bearish view

Zacks identifies slowing injectable GLP-1 momentum, pricing headwinds and fierce competition as near-term problems, while Lilly’s competing Mounjaro and Zepbound franchise is attracting investor attention.

Analyst Consensus

See all

Hold

13 analysts

$45

Current

—

Low

$47

Average

—

High

Average target implies +4.42% versus the current price.

Earnings History

BeatMissNo estimate

Peers

Abbott LaboratoriesABT · NYSE